RecallClass 2 · Action within 48 hours

Class 2 Medicines Recall: Sterling Pharmaceuticals Ltd (specials manufacturer MS 32515), KidNaps (Melatonin) 1mg in 1ml Oral Solution, EL(26)A/09

Issued 23 Feb 2026 · EL(26)A/09 · Sterling Pharmaceuticals Ltd (specials manufacturer MS 32515)

Read and act on the official notice on GOV.UK

Class 2 recall — Action within 48 hours. The MHRA uses Class 2 when: The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
What all four recall classes mean
ClassActionThe MHRA's definition
Class 1Immediate actionThe defect presents a risk of death or disability.
Class 2 this recallAction within 48 hoursThe defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
Class 3Action within 5 daysThe defect is unlikely to cause harm to the patient.
Class 4Caution in useUsually minor defects in packaging or other printed materials.

A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.

The MHRA's summary

Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are recalling all batches of KidNaps (Melatonin) 1mg in 1ml Oral Solution due to out of specification stability results.  

Affected batches

As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.

Batch numberExpiryPack sizeFirst distributed
KidNaps (Melatonin) 1mg in 1ml Oral Solution
1743Mar 2026200ml05/11/2024
1744Mar 2026200ml12/11/2024
1787Jun 2026200ml04/02/2025
1788Jun 2026200ml21/02/2025
1852Dec 2026200ml22/04/2025
1853Dec 2026200ml27/06/2025
1955Jun 2027200ml02/09/2025
1956Jun 2027200ml05/11/2025
1992Sep 2027200ml14/12/2025
1993Sep 2027200ml05/02/2026

MHRA's audience tags: Dispensing GP practices, Pharmacy

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.